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Objectives. Our aim of this study is to compare the eﬃcacy of ﬂupentixol-melitracen in the adjuvant therapy of ulcerative colitis
patients in the Chinese population. Methods. Both the RevMan 5.2 and the Stata 12.0 software are used in this study for
analysis, and a ﬁxed-eﬀect model (the Mantel-Haenszel method) or a random-eﬀect model (the DerSimonian and Laird
method) is used to merge or aggregate the risk ratio (RR) and its 95% conﬁdence intervals (CI) of included studies. Results.
Eleven trials involving 654 ulcerative colitis patients (treated group: 328; control group: 326) were analyzed in this study.
Signiﬁcant diﬀerences (RR = 1 29, 95% CI = 1 20 to 1.40, P < 0 001) between patients were observed between the two groups.
Conclusions. Our results suggested that the eﬃcacy of ﬂupentixol-melitracen in the adjuvant therapy of ulcerative colitis is better
than traditional drug treatments.
1. Introduction
Ulcerative colitis (UC) is a chronic nonspeciﬁc inﬂammatory
disease involving the colon and rectum [1, 2], and its patho-
genesis may result from changes in the colonic environment
and the patients’ psychological state [3–5]. Because the eti-
ology and pathogenesis of the disease have not been fully
elucidated, the recurrence, delayed healing course, and lack
of speciﬁcity in treatment have brought mental and psy-
chological pressure to patients. Mental and psychological
pressure also aﬀects the patient’s immune system, aﬀecting
rehabilitation. Therefore, the psychological state of ulcera-
tive colitis patients has been emphasised [6, 7]. If psycho-
social factors do contribute to the development of the disease,
then the treatment of anxiety and depression may be an
eﬀective way to treat UC. Some researchers showed that
antianxiety and depression drugs can help alleviate symptoms
of UC [8].
Flupentixol-melitracen, a clinically common anxiolytic
drug, has been shown to have a better eﬀect in adjuvant ther-
apy for common digestive disorders such as irritable bowel
syndrome and functional dyspepsia. Whether the eﬀect of
ﬂupentixol-melitracen in the adjuvant therapy of ulcerative
colitis patients in the Chinese population is superior to other
traditional drug treatments alone is controversial [9–12], so
we conducted a meta-analysis of the data from the current
study and we explored and assessed the diﬀerences between
the eﬀects of ﬂupentixol-melitracen in adjuvant therapy
compared to traditional drug treatment, by means of
extracted data.
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2. Methods
2.1. Data Sources. We use PubMed, Wanfang Data
(in Chinese), Springer, Chinese National Knowledge Infra-
structure (CNKI, in Chinese), Elsevier ScienceDirect, and
Google Scholar for searching up to December 2016. The
keywords “ﬂupentixol-melitracen,” “adjuvant therapy,”
“ulcerative colitis,” “study,” and “trial” were used.
2.2. Inclusion and Exclusion Standards of Studies
(1) Inclusion Criteria. The references included in this
study must be published in full text. All the included
trials are randomized controlled trials (RCT). Patients
included in the study were in line with ulcerative coli-
tis clinical diagnostic criteria (the revised standards of
the National Symposium on Chronic Non-infectious
Intestinal Diseases of Taiyuan). The trials included a
treated group using ﬂupentixol-melitracen combined
with traditional drugs (such as mesalazine) and a
control group only using traditional drug treatments
for ulcerative colitis patients (shown in Table 1). The
studies have a standard evaluation criteria
(2) Exclusion Criteria. The references excluded in this
study are duplicate publications and nonrando-
mized controlled trials. Subjects were conﬁrmed
cases of nonulcerative colitis. The trial did not set
up a control group. Subjects had a clear history of
mental illness.
2.3. The Eﬃcacy Standard of Treatments
(1) Cure. Clinical symptoms disappeared. Colonoscopy
revealed normal intestinal mucosa
(2) Signiﬁcantly Eﬀective. Clinical symptoms disap-
peared, and the recurrence of colonoscopy revealed
a disappearance of inﬂammation. The biopsy showed
the single diﬀuse mononuclear cells
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(3) Eﬀective. Clinical symptoms disappeared. Colonos-
copy revealed mild inﬂammation of the intestinal
mucosa or pseudopolypoid
(4) Invalid. There was no improvement in clinical
symptoms and endoscopic and pathological ﬁndings
after treatment
2.4. Evaluation of Quality and Meta-Analysis Methods. The
evaluation of the quality of each study in this study mainly
used the Jadad score. At the same time, meta-analysis was
completed in a random or ﬁxed-eﬀect model. For each study,
we used risk ratio (RR) and its 95% conﬁdence interval
(95% CI) to consolidate and summarize the statistical
analysis results. We also used the Mantel-Haenszel method
in the ﬁxed-eﬀect model [13] to obtain the combined
estimates and used the DerSimonian and Laid methods
in the stochastic eﬀect model to calculate OR and its
95% CI of each risk factor [14]. In addition, we tested
Cochran’s Q statistic to further evaluate heterogeneity
within the study and between the studies [15]. Moreover,
we also used I2 = 100%× (Q-df)/Q to further quantify the
substantial eﬀect of heterogeneity within the study and
between studies on the meta-analysis [16]. The heterogeneity
of the study mainly is reﬂected by Q statistics (P < 0 10) or I2
statistics (I2 > 50%), and then the random-eﬀect model is
used for meta-analysis. Otherwise, we used the ﬁxed-eﬀect
model. We performed all the statistical analysis using Review
Manager 5.2 and the Stata package v.12.0.
2.5. Evaluation of Publication Bias. We measured the asym-
metry of the funnel by the natural logarithmic scale of the
eﬀect size, and we used Egger linear regression [17] to evalu-
ate the publication bias.
3. Results
3.1. The Screening Process and General Characteristics of the
Study. 559 references were related to this study (PubMed:
164; Springer: 83; Elsevier ScienceDirect: 61; Google Scholar:
96; Wanfang Data: 68; CNKI: 87). After the selection process
by deleting irrelevant/duplicate records as shown in Figure 1,
Fifty-one records were primarily involved in this study.
Twenty-three of these records were removed by screening
the abstracts (10 were not RCT; 13 were review articles).
Finally, 28 trials were given a comprehensive review, and
559 potentially relevant records identiﬁed and screened
(PubMed 164; Springer 83; Elsevier ScienceDirect 61;
Google Scholar 96; Wanfang 68; CNKI 87)
51 potentially relevant records aer duplicates or
irrelevant records removed.
23 excluded based on review of abstract
(13 reviews; 10 not RCT)
28 retrieved for detailed assessment
17 excluded based on review of full text (10
only reported ﬂupentixol-melitracen but
not for comparison. 7 excluded because
the data is not available) 
11 seperated trials inclued in meta-analysis 
Figure 1: Flow diagram for selection of studies. 559 potentially relevant records identiﬁed and screened (PubMed: 164; Springer: 83; Elsevier
ScienceDirect: 61; Google Scholar: 96; Wanfang Data: 68; CNKI:87); 51 potentially relevant records after duplicates or irrelevant records
removed; 23 excluded based on the abstract (13 reviews; 10 not RCT); 28 retrieved for detailed assessment; 17 excluded based on review of
the full text (10 only reported ﬂupentixol-melitracen, but not for comparison; 7 due to nonavailable data); 11 separate studies included in
meta-analysis.
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11 trials were analyzed after deleting 17 unsuitable trials
(10 only reported ﬂupentixol-melitracen data, and 7 did not
provide available data).
As is shown in Table 1, there are 11 trials [9–12, 18–24] in
this study. The published years of recruited researches were
between 2006 and 2015. A total of 654 ulcerative colitis
patients (treated group: 328; control group: 326) were
included in this study. The sample sizes of this study were
between 40 and 80. The eleven trials were randomized con-
trolled trials (RCT). Two had a Jadad score of 3 (Table 2),
and nine had a Jadad score of 2.
3.2. Overall Eﬃcacy of Flupentixol-Melitracen in the
Adjuvant Therapy of Ulcerative Colitis. The overall eﬀects
of ﬂupentixol-melitracen in the adjuvant therapy of ulcera-
tive colitis patients with this study are revealed in Figure 2.
Eleven trials involving 654 ulcerative colitis patients with
ﬂupentixol-melitracen in the adjuvant therapy were analyzed
in this study. No heterogeneities between studies (Q2 = 6 40,
I2 = 0%, P > 0 1) were observed, so we used the ﬁxed-eﬀect
model to compare eﬃcacy between the treated group and
the control group. Signiﬁcant diﬀerences (RR = 1 29, 95%
CI = 1 20 to 1.40, P < 0 001) in patients were observed
between the two groups, suggesting that the eﬃcacy of
ﬂupentixol-melitracen in the adjuvant therapy of ulcerative
colitis in the treated group may be better than that in the
control group.
3.3. Publication Bias Analysis Assessment. The almost sym-
metrical funnel plot (Figure 3) and Egger’s linear regression
test (t = −0 83, P > 0 05) of the ﬂupentixol-melitracen eﬃcacy
in the adjuvant therapy of ulcerative colitis patients showed
that there was no publication bias existing in our study.
4. Discussion
Some studies [11, 12, 20, 22, 23] assessed the eﬀects of
ﬂupentixol-melitracen in the adjuvant therapy versus other



















Li et al. 2006 [23] Yes NA NA NA Yes 2
Hu 2011 [22] Yes NA NA NA Yes 2
Fan 2011 [19] Yes NA NA NA Yes 2
Yang 2013 [24] Yes NA NA NA Yes 2
Hu 2013 [21] Yes NA NA NA Yes 2
Duan 2014 [18] Yes NA NA NA Yes 2
Huang 2014 [9] Yes NA NA NA Yes 2
Xie et al. 2014 [11] Yes Yes NA NA Yes 3
Li 2014 [10] Yes NA NA NA Yes 2
Feng 2014 [20] Yes NA NA NA Yes 2
Lin 2015 [12] Yes Yes NA NA Yes 3
Study or subgroup ExperimentalEvents Total
Control
Events Total Weight
Risk ratio Risk ratio




















































































0.2 0.5 1 2 5
Favours experimental Favours control
Total (95% CI)
Total events
Heterogeneity: chi2 = 6.40, df = 10 (P = 0.78); I2 = 0%
Test for overall eﬀect: Z = 6.55 (P < 0.00001)
Figure 2: Forest plot of ﬂupentixol-melitracen in the adjuvant therapy of ulcerative colitis with the experimental group vs. the control group.
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traditional drug treatments for ulcerative colitis patients. But
confusing results were found, as the sample sizes of the stud-
ies were not large enough and the statistical eﬃciency of the
studies was relatively low. Thus, we combined the eleven tri-
als which included the 654 ulcerative colitis patients (treated
group: 328; control group: 326). Signiﬁcant diﬀerences
(RR = 1 29, 95% CI = 1 20 to 1.40, P < 0 001) in patients were
observed between the control group and the treated group.
Ulcerative colitis (UC) is a chronic nonspeciﬁc intestinal
inﬂammation. It mainly aﬀects the mucosa and submucosa
of the colon. It spreads from the distal colon to the proximal
part of the colon and gradually aﬀects the whole colon [25].
The clinical manifestations usually include abdominal pain,
diarrhea, mucus pus, blood, and other symptoms. Symptoms
may be persistent or recurrent and may be associated with
the skin, mucous membranes, joints, and other parenteral
performance. The current treatment of ulcerative colitis often
uses 5-aminosalicylic acid drugs, hormones, immunosup-
pressive agents, and other drugs. Patients are symptomatic
for a long period and the symptoms are recurrent. It has a
great negative psychological impact on the patient and is
often accompanied by depression, anxiety, and other symp-
toms, which will aﬀect the eﬀect of disease treatment.
Ulcerative colitis is a chronic inﬂammatory disease and
has no special treatment [26]. The current application of
anti-inﬂammatory drugs is mostly aminosalicylic acid,
including mesalazine, 5-aminosalicylic acid, and sulfasala-
zine. The disease is a chronic gastrointestinal disease, which
will lead to excessive diarrhea in patients. It can also lead to
loss of nutritional ingredients in patients, whichwill endanger
their lives. Therefore, it is essential to take eﬀective treatment
combined with the necessary antianxiety drug therapies to
improve the patient’s quality of life.
Research has shown that psychological factors alter
brain-gut axis function, stimulating the autonomic nervous
system; promote the release of various neurotransmitters;
increase the activity of immune cells; and alter the interaction
between bacteria and mucosa, which work together to
damage the intestinal mucosa and lead to the occurrence of
ulcerative colitis [27]. Flupentixol-melitracen is a compound
preparation containing ﬂupentixol and melitracen. Flupen-
tixol acts on the D2 receptor, promotes the synthesis and
release of dopamine, and increases the content of dopamine
in synaptic space, which play an antianxiety and antidepres-
sion role. Melitracen is a biphasic antidepressant, which can
inhibit the uptake of norepinephrine and serotonin through
the presynaptic membrane inducing the increase of mono-
amine transmitters in synaptic space. The mixture of the
two ingredients will combat depression and anxiety.
Although the included systematic studies were random-
ized controlled trials, the Jadad scores of the selected trials
were 2 to 3, probably indicating a lower literature quality.
Further studies with large-sample, multicenter, and prospec-
tive randomized trials are required to conﬁrm the results of
the current study.
5. Conclusions
Our results suggested that the eﬃcacy of ﬂupentixol-
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Figure 3: Funnel plot of ﬂupentixol-melitracen in the adjuvant therapy of ulcerative colitis with the experimental group vs. the control group.
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the experimental group is better than that in traditional
drug treatments. The results of this study show that
ﬂupentixol-melitracen in the adjuvant therapy is a safe and
eﬀective treatment, although a multicenter and large-sample
randomized controlled study is still needed to further conﬁrm
the results of this study.
Conflicts of Interest
The authors declare that they have no conﬂicts of interest.
References
[1] J. Xu, M. Tam, S. Samaei et al., “Mucoadhesive chitosan hydro-
gels as rectal drug delivery vessels to treat ulcerative colitis,”
Acta Biomaterialia, vol. 48, pp. 247–257, 2017.
[2] T. Watanabe, Y. Ajioka, K. Mitsuyama et al., “Comparison
of targeted vs random biopsies for surveillance of ulcerative
colitis-associated colorectal cancer,”Gastroenterology, vol. 151,
no. 6, pp. 1122–1130, 2016.
[3] N. Rachel, H. Aubrey, S. Noelle, H. Doug, and W. Helané,
“P-058 depression and anxiety in inﬂammatory bowel disease:
a systematic review,” Inﬂammatory Bowel Diseases, vol. 20,
article S51, 2014.
[4] P. Hindryckx, V. Jairath, and G. D'Haens, “Acute severe ulcer-
ative colitis: from pathophysiology to clinical management,”
Nature Reviews Gastroenterology & Hepatology, vol. 13,
no. 11, pp. 654–664, 2016.
[5] V. Gunterberg, M. Simren, L. Ohman et al., “Autonomic ner-
vous system function predicts the inﬂammatory response over
three years in newly diagnosed ulcerative colitis patients,”
Neurogastroenterology & Motility, vol. 28, no. 11, pp. 1655–
1662, 2016.
[6] C. W. Sobrado and L. F. Sobrado, “Management of acute
severe ulcerative colitis: a clinical update,” Arquivos Brasileiros
de Cirurgia Digestiva, vol. 29, no. 3, pp. 201–205, 2016.
[7] C. Mittermaier, C. Dejaco, T. Waldhoer et al., “Impact of
depressive mood on relapse in patients with inﬂammatory
bowel disease: a prospective 18-month follow-up study,”
Psychosomatic Medicine, vol. 66, no. 1, pp. 79–84, 2004.
[8] M. Schoultz, “The role of psychological factors in inﬂamma-
tory bowel disease,” British Journal of Community Nursing,
vol. 17, no. 8, pp. 370–374, 2012.
[9] W. H. Huang, “The eﬀect of deanxit combined with mesala-
zine on treating ulcerative colitis,” Contemporary Medicine,
vol. 20, no. 10, p. 118, 2014.
[10] Z. G. Li, “Exploration of ﬂupentixol and melitracen combined
with mesalazine for treatment of ulcerative colitis,” Nei Mon-
gol Journal of Traditional Chinese Medicine, vol. 33, no. 6,
pp. 51-52, 2014.
[11] R. Xie, C. C. Gap, S. N. Wu, W. Yan, and T. H. Ma, “Clinical
observation of ﬂupentixol and melitracen combined with
mesalazine for treatment of ulcerative colitis patients with anx-
iety and depression,” Chinese Journal of Gastroenterology,
vol. 19, no. 10, pp. 599–602, 2014.
[12] R. P. Lin, “To study the clinical evaluation of deanxit com-
bination with mesalazine treatment patients with ulcerative
colitis,” Journal of North Pharmacy, vol. 12, no. 11,
pp. 18-19, 2015.
[13] N. Mantel and W. Haenszel, “Statistical aspects of the analysis
of data from retrospective studies of disease,” Journal of the
National Cancer Institute, vol. 22, no. 4, pp. 719–748, 1959.
[14] R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,”
Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986.
[15] J. Lau, J. P. Ioannidis, and C. H. Schmid, “Quantitative syn-
thesis in systematic reviews,” Annals of Internal Medicine,
vol. 127, no. 9, pp. 820–826, 1997.
[16] J. P. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman,
“Measuring inconsistency in meta-analyses,” BMJ, vol. 327,
no. 7414, pp. 557–560, 2003.
[17] M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias
in meta-analysis detected by a simple, graphical test,” BMJ,
vol. 315, no. 7109, pp. 629–634, 1997.
[18] S. F. Duan, “The investigation of the eﬀect of deanxit com-
bined with mesalazine on treating ulcerative colitis,” Chinese
and Foreign Medical Research, vol. 12, no. 25, pp. 56-57, 2014.
[19] D. F. Fan, “Flupentixol and melitracen combined with mesala-
zine on treating ulcerative colitis,” Chinese Remedies & Clinics,
vol. 11, no. 1, pp. 68-69, 2011.
[20] X. C. Feng, “Curative eﬀect of furazolidone and methicillin in
the treatment of ulcerative colitis,” Shenzhen Journal of
Integrated Traditional Chinese and Western Medicine, vol. 24,
no. 9, pp. 99-100, 2014.
[21] S. C. Hu, “The clinical eﬀect of deanxit combined with mesala-
zine in the treatment of ulcerative colitis with anxiety and
depression,” Healthy Reading Magazines, vol. 8, p. 424, 2013.
[22] Y. Hu, “Clinical analysis of 46 cases of ulcerative colitis treated
with combination therapy,” Xinjiang Medicine, vol. 41, no. 10,
pp. 92–94, 2011.
[23] X. H. Li, J. S. Li, and L. F. Chen, “Clinical eﬃcacy of ﬂupentixol
and melitracen treatment with ulcerative colitis patients with
symptoms of anxiety and depression,” Shanxi Medical Journal,
vol. 35, no. 3, pp. 246-247, 2006.
[24] Z. Y. Yang, “Analysis of the clinical eﬀect of deanxit combined
with mesalazine in the treatment of ulcerative colitis,” Modern
Diagnosis and Treatment, vol. 24, no. 17, p. 3920, 2013.
[25] F. Wang, J. Feng, Q. Gao et al., “Carbohydrate and protein
intake and risk of ulcerative colitis: systematic review and
dose-response meta-analysis of epidemiological studies,” Clin-
ical Nutrition, vol. 36, no. 5, pp. 1259–1265, 2017.
[26] A. D. Vickers, C. Ainsworth, R. Mody et al., “Systematic review
with network meta-analysis: comparative eﬃcacy of biologics
in the treatment of moderately to severely active ulcerative
colitis,” PLoS One, vol. 11, no. 10, article e0165435, 2016.
[27] J. E. Mawdsley and D. S. Rampton, “Psychological stress in
IBD: new insights into pathogenic and therapeutic implica-
tions,” Gut, vol. 54, no. 10, pp. 1481–1491, 2005.
















































































Submit your manuscripts at
www.hindawi.com
